ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Gujarat Themis Biosyn Investor Presentation: Key Takeaways

GTBL reported strong Q1 FY27 results with 22.1% revenue growth and 49.4% EBITDA growth. Strategy focuses on global CDMO expansion through acquisitions and forward integration into API production.

Highlights
MarginsEBITDA margin improved to 47.5% due to economies of scale.
Demand visibilityStable market demand reflecting healthy sales volumes.

Growth

Revenue rose 22.1% YoY to Rs. 43.8 Cr; PAT increased 22.1% to Rs. 11.1 Cr.

Outlook

Major inorganic expansion via Sanofi brands and MicroBiopharm Japan. New fermentation and R&D units operational.

Risks

Old plant depreciation, higher employee costs, and regulatory approvals for Japanese acquisition.

Source

Investor Presentation filed with BSE, NSE: GUJTHEM. Summary written with AI assistance from the document.

Read the document ↗

Gujarat Themis Biosyn Ltd: key numbers

Share price
₹389.15
Market cap
₹5,065 Cr
Revenue (annual)
₹165.8 Cr
Net profit (annual)
₹46.68 Cr
P/E (TTM)
104.0×Sector 43.8×
Promoter holding
59.33%-11.53% QoQ
FII holding
3.80%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Gujarat Themis Biosyn Ltd

All →